On Monday, Standard BioTools Inc (NASDAQ: LAB) was 5.53% up from the session before settling in for the closing price of $1.99. A 52-week range for LAB has been $1.21 – $3.04.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
It was noted that within the last five years, the titan of the Healthcare sector saw sales slided by -0.06%. When this article was written, the company’s average yearly earnings per share was at 62.06%. With a float of $359.12 million, this company’s outstanding shares have now reached $371.15 million.
The extent of productivity of a business whose workforce counts for 539 workers is very important to gauge. In terms of profitability, gross margin is 48.57%, operating margin of -81.68%, and the pretax margin is -79.83%.
Standard BioTools Inc (LAB) Insider and Institutional Ownership
Also, it is sometimes useful to examine the sentiment of large-scale investors toward Standard BioTools Inc stocks. The insider ownership of Standard BioTools Inc is 3.24%, while institutional ownership is 71.55%. The most recent insider transaction that took place on Sep 09 ’24, was worth 91,725. Before that another transaction happened on Aug 27 ’24, when Company’s Director bought 250,000 for $2.19, making the entire transaction worth $546,750. This insider now owns 54,025,821 shares in total.
Standard BioTools Inc (LAB) Latest Financial update
According to the Wall Street analysts, stocks earnings will be around 62.06% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will plunge by -8.06% during the next five years compared to 8.72% growth over the previous five years of trading.
Standard BioTools Inc (NASDAQ: LAB) Trading Performance Indicators
You can see what Standard BioTools Inc (LAB) is doing with its current performance indicators. In the most recent quarter, the stock posted a quick ratio of 3.41. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 5.08.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.71, a number that is poised to hit -0.06 in the next quarter and is forecasted to reach -0.20 in one year’s time.
Technical Analysis of Standard BioTools Inc (LAB)
The latest stats from [Standard BioTools Inc, LAB] show that its last 5-days average volume of 3.83 million was superior to 2.47 million than last year’s volume. As of the previous 9 days, the stock’s Stochastic %D was 59.44%. Additionally, its Average True Range was 0.13.
During the past 100 days, Standard BioTools Inc’s (LAB) raw stochastic average was set at 74.17%, which indicates a significant increase from 73.33% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 58.03% in the past 14 days, which was lower than the 100.80% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $1.9300, while its 200-day Moving Average is $2.2300. Now, the first resistance to watch is $2.1400. This is followed by the second major resistance level at $2.1900. The third major resistance level sits at $2.2600. If the price goes on to break the first support level at $2.0200, it is likely to go to the next support level at $1.9500. The third support level lies at $1.9000 if the price breaches the second support level.
Standard BioTools Inc (NASDAQ: LAB) Key Stats
There are 371,154K outstanding shares of the company, which has a market capitalization of 791.36 million. As of now, sales total 106,340 K while income totals -74,660 K. Its latest quarter income was 37,210 K while its last quarter net income were -45,720 K.
